68Ga-ICAM-1pep PET/CT in Cancer Patients

Launched by PEKING UNIVERSITY CANCER HOSPITAL & INSTITUTE · Oct 19, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging technique called 68Ga-ICAM-1pep PET/CT to see how well it can help doctors predict treatment outcomes for patients with advanced cancer who are receiving radiotherapy. The goal is to find out if this imaging can provide useful information about the cancer's behavior and response to treatment. Participants in the study will receive a single injection of a small amount of the imaging agent, and then undergo PET/CT scans to take pictures of their cancer.

To be eligible for this trial, participants should be between 18 and 80 years old, have a good performance status (meaning they are able to carry out daily activities), and have lung cancer, esophagus cancer, cervical cancer, or other specific cancers that require imaging. Those who are pregnant, have serious liver or kidney problems, or cannot follow the imaging procedures will not be able to participate. If you join the study, you can expect to have the injection and then undergo imaging to help assess your cancer, all while being closely monitored by the study team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18-80 years old;
• • 2. ECOG score 0 or 1 point;
• • 3. Patients with suspected or confirmed lung cancer, esophagus cancer, cervical cancer or other cancers who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging.
• Exclusion Criteria:
• • 1. Pregnant or nursing;
• • 2. Severe hepatic or renal dysfunction;
• • 3. Low WBC (less than 3 x 10\^9/L);
• • 4. Unable to comply with the PET/CT imaging procedures.